Bortezomib With or Without Docetaxel in Treating Patients With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2004-07-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy such as docetaxel use different ways to stop tumor
cells from dividing so they stop growing or die. Bortezomib may stop the growth of cancer
cells by blocking the enzymes necessary for cancer cell growth. It is not yet known whether
bortezomib is more effective with or without docetaxel in treating patients with advanced
non-small cell lung cancer.
PURPOSE: Randomized phase II trial to compare the effectiveness of bortezomib with or without
docetaxel in treating patients who have relapsed or refractory stage IIIB or stage IV
non-small cell lung cancer.